A recent meta-analysis of 119 randomized controlled trials in patients with CKD [19] found that ACE inhibitors compared to ARBs were associated with higher probabilities of reducing kidney failure and cardiovascular death and that ACE inhibitors, but not ARBs, reduced all-cause death compared to control. Here, ACE is linked to chronic kidney disease.